Manzoor khan
@mzk1987.bsky.social
📤 213
📥 329
📝 7
Hemato-oncologist ,internist,politically free BMT Fellow QEHB,UK Special interest IN MM/Lymphoma/BMT
reposted by
Manzoor khan
Ajay Major, MD, MBA
about 1 year ago
Ibru+ven x 16➡️ibru+obinu x 6 if MRD+ (if uMRD-, obs)
#ASH24
: - 84 pts, 7% TP53mut, 57% very high CLL-IPI - 21% uMRD➡️obs: 2-yr PFS 94% - 79% MRD+➡️IO intensification: 60% achieved subsequent uMRD, 2-yr PFS 92% 60% of all pts achieved uMRD. Time-limited tx strategies ftw!
#leusm
0
2
1
reposted by
Manzoor khan
Muzaffar Qazilbash
about 1 year ago
#ASH24
Circulating Tumor Cells (CTC) as a biomarker for TE NDMM in Perseus trial (D-VRd vs. VRd) -CTC is an independent prognostic factor -HR cytogenetics + CTC => dismal outcome
#mmsm
#bmtsm
ash.confex.com/ash/2024/web...
loading . . .
Paper: Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Indu...
https://ash.confex.com/ash/2024/webprogram/Paper199550.html
0
4
2
reposted by
Manzoor khan
Stephen Liu
about 1 year ago
ASCO has released an updated Rapid Recommendation for stage III NSCLC in JCO Oncology Practice. Update now includes targeted therapy: consolidation osimertinib after chemoradiation for
#EGFR
NSCLC, adjuvant osimertinib or alectinib for resected EGFR or ALK NSCLC.
#LCSM
ascopubs.org/doi/10.1200/...
loading . . .
Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights | JCO Oncology Practice
https://ascopubs.org/doi/10.1200/OP-24-00784
0
35
17
@szusmani.bsky.social
At PCUH(Pakistan PSH).....Will try to get his full presentation very soon.thoughts provoking talk...we are blessed ,
about 1 year ago
0
3
1
Updated breast cancer algorthim with updated data....
about 1 year ago
0
2
1
@medihumdani.bsky.social
Great Talk by Dr.Mehdi Hamdini bhai at PCUH (PSH) .Very informative talk. Can we have the whole ppt?
about 1 year ago
2
1
0
Nice algorithmic approach
about 1 year ago
0
3
1
Nice summary
about 1 year ago
0
0
0
Looks much similar to X. Hopefully, it will be a great experience with skyblue. Nice transition from X to sky blue.
about 1 year ago
0
1
0
you reached the end!!
feeds!
log in